---
document_datetime: 2025-10-22 11:38:44
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/venclyxto-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: venclyxto-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 17.8431086
conversion_datetime: 2025-12-31 03:50:45.982453
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Venclyxto

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a group of | 21/10/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000291886                     | variations. C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z To amend the final report milestone for: Study P22-905 from Q4 2025 to Q4 2026, Study M16-185 from Q4 2025 to Q1 2028 and Study P16-562 from Q1 2026 to Q2 2026 in the RMP. C.I.11.z To remove study P22-907 from the RMP following the assessment in procedure EMA/VR/0000245044 and to remove Neutropenia and Serious Infection from the   |            |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Variation type II / EMA/VR/0000282341 | This was an application for a group of variations. B.I.a.2 Changes in the manufacturing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 25/09/2025 |

<div style=\"page-break-after: always\"></div>

| process of the active substance - B.I.a.2.a Minor change in the manufacturing of the active substance - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - Minor change in the manufacturing of the active substance - Accepted B.I.a.3 Change in batch size (including size ranges) of active substance or intermediate used in the manufacturing process of the active substance - Up to 10-fold increase compared to the originally approved batch size - Accepted B.I.a.3 Change in batch size (including size ranges) of active substance or intermediate used in the manufacturing process of the active substance - Up to 10-fold increase compared to the originally approved batch size - Accepted B.I.a.1 Change in the manufacturer of a   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| B.I.a.2.a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| batch                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| B.I.a.3.a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| batch                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| B.I.a.3.a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| starting material/reagent/intermediate used                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| in the manufacturing process of the active                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| substance or change in the manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| (including where relevant quality control                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| testing sites) of the active substance, where                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| no Ph. Eur. Certificate of Suitability is part of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| the approved dossier - B.I.a.1.z Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted                                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the specification with its corresponding test method - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / |
| reagent used in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                  |
| of the active substance - B.I.b.1.c Addition of a new specification parameter to the specification with its corresponding test                                                                                                                                                                                                                                                                                                             |
| method - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                          |
| B.I.b.1 Change in the specification                                                                                                                                                                                                                                                                                                                                                                                                        |
| parameters and/or limits of an active                                                                                                                                                                                                                                                                                                                                                                                                      |
| substance, starting material / intermediate /                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the specification with its corresponding test method - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the specification with its corresponding test method - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the specification with its corresponding test method - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the specification with its corresponding test   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the specification with its corresponding test method - Accepted                                                                                                                                                                                                                                                                                                                                                                                       |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the specification with its corresponding test method - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted B.I.b.2 Change in test procedure for active substance or starting |

<div style=\"page-break-after: always\"></div>

|                                       | substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.b Substantial change to the manufacturing process of the active substance which may have a significant impact on the quality, safety or efficacy of the medicinal product -   |            |      |                                                                               |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|-------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000246380 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 24/07/2025 | SmPC | For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                                       | quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.2, 4.9 and 5.2 of the SmPC in order to inform no adjustment is needed in patients with ESRD requiring dialysis and to add information on the pharmacokinetics data for patients with ESRD requiring dialysis, based on final results from study M19-065, 'Evaluation of the Pharmacokinetics and Safety of Venetoclax in Subjects with Impaired Renal Function'. The RMP version 10.0 has also been submitted.   |            |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Variation type II / EMA/VR/0000245044 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Submission of additional clinical and non-clinical studies, including BE-studies. - Accepted Submission of the final report from study P22-907 listed as a category 3 PASS in the RMP. This is a non-interventional cross- sectional study evaluating the effectiveness of venetoclax risk minimisation measures among haematologists in Europe.                                                                                                     | 10/07/2025 |
| PSUR / EMA/PSUR/0000257855            | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |